Serbia gives Galenika sale another month
BELGRADE, April 30
BELGRADE, April 30 (Reuters) - Serbia on Tuesday extended for another month a deadline for bids for its indebted state-run drugmaker Galenika Pharmaceuticals, with the U.S.-based unit of Canada's Valeant Pharmaceuticals International so far the only potential partner.
The finance ministry said the new deadline was 4 p.m. (1400 GMT) on May 31, the third extension since offers were first invited on Jan. 14.
With a workforce of 2,700, the Belgrade-based Galenika has accumulated debt of about 170 million euros ($223 million), and needs about 50 million euros in additional capital in 2013.
Its sale is part of an effort by the government to offload a number of bloated, loss-making state enterprises to ease the burden on its budget.
Earlier in April, the finance ministry said the U.S.-based unit of Valeant was the only potential partner so far, having met all the conditions of the tender.
- Exclusive: Malaysia plane probe narrows on mid-air disintegration - source
- Radar showed missing plane may have turned back: Malaysia military
- Missing Malaysian jet may have disintegrated in mid-air: source |
- Malaysian plane presumed crashed; questions over false IDs |
- Merkel raps Putin as Russian forces tighten grip on Crimea |